GlassScriptPhysician profile
Emily Shaughnessy
NPI 1295155232
$5,839.67
in general payments reported to CMS, 2019-2025
22 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.74 · 2022: $761 · 2023: $2,335 · 2024: $1,476 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,900 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,899.73 |
| Education | $118.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,411.58 | 2021-2025 | Skyrizi, Rinvoq |
| Leo Pharma INC. | $916.07 | 2022-2025 | Adbry |
| Incyte Corporation | $684.00 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $573.79 | 2022-2024 | Sotyktu |
| Amgen INC. | $521.72 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $297.68 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Lilly USA, LLC | $287.24 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $266.48 | 2022-2025 | |
| Pfizer INC. | $198.64 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $170.35 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $92.11 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Sun Pharmaceutical Industries INC. | $65.63 | 2023-2025 | Ilumya |
| Dermavant Sciences, INC. | $57.60 | 2023 | Vtama |
| Ucb, INC. | $42.27 | 2024 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $39.77 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.68 | 2024-2025 | Cabtreo |
| Lnhc, INC | $24.82 | 2025 | Zelsuvmi |
| Organon LLC | $24.26 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $20.63 | 2024 | Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.94 | 2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $17.42 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Shaughnessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.